title: Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
abstract: Diabetic ketoacidosis is characterized by hyperglycemia, anion-gap acidosis, and increased plasma ketones. After the resolution of hyperglycemia, persistent diuresis is rare. We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia. Physicians should consider euglycemic diabetic ketoacidosis in the differential diagnosis of patients treated with SGLT2 inhibitors.
authors.affiliation: Department of Internal Medicine, Ohkubo Hospital, Japan.
authors.forename: Junichiro
authors.initials: J
authors.lastname: Adachi
authors.forename: Yuusuke
authors.initials: Y
authors.lastname: Inaba
authors.forename: Chisato
authors.initials: C
authors.lastname: Maki
mesh_terms: D000328:Adult; D000068896:Canagliflozin / Q000008:administration & dosage* / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis*; D003937:Diagnosis, Differential; D004231:Diuresis; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin